San Diego-based mostly Viking Therapeutics marked alone as a serious competitor during the weight loss drug current market in February immediately after revealing promising data from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection and in M